Palmitoyl tripeptide-8
Based on 1 Customer Validation
Palmitoyl tripeptide-8 is an immunomodulatory peptide and neurotransmitter inhibitory peptide. Palmitoyl tripeptide-8 inhibits the activation of the NF-κB pathway and the production of pro-inflammatory cytokines (IL-8, IL-6, and TNF-α). Palmitoyl tripeptide-8 activates the cutaneous opioid system and reduces CGRP release. Palmitoyl tripeptide-8 decreases the number of dilated capillaries, the size of dilated vessels, and the degree of edema in skin explants treated with Substance P (HY-P0201). Palmitoyl tripeptide-8 is used as an active ingredient in cosmetics for sensitive skin. Palmitoyl tripeptide-8 is utilized in research related to sensitive skin.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.58%
- No. CAS: 936544-53-5
- Fòrmula: C37H61N9O4
- Peso molecular:695.94
-
Almacenamiento:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Ver todos los productos específicos de isoformas Opioid Receptor
MoreVer todos los productos específicos de isoformas TNF Receptor
More
Actividad biológica
Descripciòn
IC50 & Target
[1]|
IL-6 |
IL-8 |
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 936544-53-5
-
Appearance Solid
-
Peso molecular 695.94
-
Fòrmula C37H61N9O4
-
Color White to off-white
-
Sequence
{palmitoyl-His}-{d-Phe}-Arg-NH2
-
Sequence Shortening
{palmitoyl-His}-{d-Phe}-R-NH2
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvente y solubilidad
In Vitro:
DMSO : 100 mg/mL (143.69 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
Pureza y Documentación
-
Ficha de datos (271 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.4369 mL | 7.1845 mL | 14.3691 mL | 35.9226 mL |
| 5 mM | 0.2874 mL | 1.4369 mL | 2.8738 mL | 7.1845 mL | |
| 10 mM | 0.1437 mL | 0.7185 mL | 1.4369 mL | 3.5923 mL | |
| 15 mM | 0.0958 mL | 0.4790 mL | 0.9579 mL | 2.3948 mL | |
| 20 mM | 0.0718 mL | 0.3592 mL | 0.7185 mL | 1.7961 mL | |
| 25 mM | 0.0575 mL | 0.2874 mL | 0.5748 mL | 1.4369 mL | |
| 30 mM | 0.0479 mL | 0.2395 mL | 0.4790 mL | 1.1974 mL | |
| 40 mM | 0.0359 mL | 0.1796 mL | 0.3592 mL | 0.8981 mL | |
| 50 mM | 0.0287 mL | 0.1437 mL | 0.2874 mL | 0.7185 mL | |
| 60 mM | 0.0239 mL | 0.1197 mL | 0.2395 mL | 0.5987 mL | |
| 80 mM | 0.0180 mL | 0.0898 mL | 0.1796 mL | 0.4490 mL | |
| 100 mM | 0.0144 mL | 0.0718 mL | 0.1437 mL | 0.3592 mL |
Keywords
- Palmitoyl tripeptide-8
- 936544-53-5
- Palmitoyl tripeptide8
- Palmitoyl tripeptide 8
- NF-κB
- Interleukin Related
- Opioid Receptor
- CGRP Receptor
- TNF Receptor
- Nuclear factor-κB
- Nuclear factor-kappaB
- IL
- Calcitonin gene-related peptide receptor
- Tumor Necrosis Factor Receptor
- TNFR
- NF-κB pathway
- CGRP
- pro-inflammatory cytokine
- substance P-exposed skin explants
- UVB-irradiated keratinocytes
- IL-8
- α-melanocyte stimulating hormone
- IL-1-stimulated fibroblasts
- sodium dodecyl sulfate-induced skin irritation
- cutaneous opioid system
- Inhibitor
- inhibitor
- inhibit